Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast cancer prevention trials.

D J Rhodes1, L C Hartmann, E A Perez

  • 1Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Rhodes.Deborah@mayo.edu

Current Oncology Reports
|December 21, 2000
PubMed
Summary

Tamoxifen may reduce breast cancer incidence by nearly half for high-risk women. However, results vary across studies due to population differences, making its widespread use for breast cancer prevention still under evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016
Same author

Study of correlation between forced vital capacity and demand for healthcare services in severe asthmatics.

Multidisciplinary respiratory medicine·2015
Same author

Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Investigational new drugs·2014
Same author

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Area of Science:

  • Oncology
  • Pharmacology
  • Preventive Medicine

Background:

  • Chemoprevention offers a new strategy to decrease breast cancer incidence using drug therapy.
  • Tamoxifen has been investigated in three randomized trials for its chemopreventive efficacy with conflicting outcomes.

Purpose of the Study:

  • To review eligibility criteria, treatment plans, and results from randomized trials of tamoxifen versus placebo for breast cancer prevention.
  • To examine data on raloxifene's effect on breast cancer incidence.

Main Methods:

  • Review of three published randomized, controlled trials comparing tamoxifen to placebo.
  • Analysis of data regarding tamoxifen and raloxifene in breast cancer prevention.

Main Results:

  • One trial (NSABP Breast Cancer Prevention Trial) indicated tamoxifen reduced breast cancer incidence by almost half.
  • Other trials (British and Italian) found no significant benefit, possibly due to variations in study populations and methodologies.

Conclusions:

  • Tamoxifen is a potential chemoprevention option for high-risk women, but its efficacy is debated.
  • The Study of Tamoxifen and Raloxifene (STAR) trial is ongoing to compare tamoxifen and raloxifene; current use of raloxifene for primary prevention is premature.

Related Experiment Videos